The biopharma industry has hit a setback in its ambition to leverage President Donald Trump’s “big, beautiful bill” to amend ...

Trump has threatened that pharmaceutical import tariffs could clock in at “25% or higher.” The President first floated the ...

Four U.S. senators have reintroduced a bipartisan bill focused on strengthening the pharmaceutical supply chain by ...

European marketers are feeling the squeeze, with a combination of shrinking budgets, rising targets and tightening compliance requirements piling on the pressure, ...

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...

Amid a spate of high-profile investments in U.S. pharmaceutical production, two contract manufacturers are getting in on the ...

Neurology specialist Supernus Pharmaceuticals will snap up Sage Therapeutics, which was once valued at more than $9 billion, ...

Roche and AbbVie have once again come up short in their attempt to gain an additional indication for their blockbuster blood ...

Founder and Global CEO of Doceree, returns with Season 2 of “The Next Marketing with HJ”—a one-of-a-kind, knowledge-packed ...

In conversation with Fierce Biotech’s Chris Hayden, Austin Read, head of PPD™ CorEvitas™ Precision Medicine, Thermo Fisher ...

Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug ...

A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile. | A second patient has ...